Updated guidance for PAT-DX1 phase 1 clinical study

ASX Announcements

Patrys Limited (ASX: PAB), has advised that, based on recent updates from its Contract Development Manufacturing Organisation (CDMO) regarding the timing of availability of clinical-grade PAT-DX1, it now expects to initiate the Phase 1 clinical trial of PAT-DX1 in calendar year 2024.

Click here to read the ASX release.